Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:55:12 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Q:VRTX - VERTEX PHARMACEUTICAL - https://www.vrtx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VRTX - Q0.1465.50·477.393.6477.92+19.114.21,621.6766,84930,747459.69  478.28  459.00519.68  362.5019:43:45Jan 2315 min RT 2¢

Recent Trades - Last 10 of 30747
Time ETExPriceChangeVolume
19:43:45Q477.1718.361
19:39:28Q470.0011.1918
19:39:14Q467.468.651
19:38:26Q476.2017.391
19:13:15Q475.0116.2015
18:55:36Q475.0016.1912
18:33:29Q477.3818.571
18:25:28Q477.0018.195
18:25:28Q477.0018.191
18:25:28Q477.0018.191

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-23 12:56U:VRTXNews ReleaseBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
2026-01-20 16:00U:VRTXNews ReleaseVertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
2026-01-11 17:00U:VRTXNews ReleaseVertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
2025-12-22 16:00U:VRTXNews ReleaseVertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
2025-12-16 12:00U:VRTXNews ReleaseFrom Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
2025-12-06 07:01U:VRTXNews ReleaseVertex Presents New Data on CASGEVY(TM), Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
2025-11-19 16:00U:VRTXNews ReleaseVertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3
2025-11-08 17:15U:VRTXNews ReleaseVertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
2025-11-03 16:02U:VRTXNews ReleaseVertex Reports Third Quarter 2025 Financial Results
2025-10-27 16:00U:VRTXNews ReleaseVertex to Participate in the UBS Global Healthcare Conference on November 11
2025-10-23 09:00U:VRTXNews ReleaseVertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK(TM) at the North American Cystic Fibrosis Conference
2025-10-17 09:04U:VRTXNews ReleaseVertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
2025-10-06 16:00U:VRTXNews ReleaseVertex to Announce Third Quarter 2025 Financial Results on November 3rd
2025-09-25 07:45U:VRTXNews ReleaseVertex Announces Key Advancements Across Kidney Portfolio
2025-09-23 09:00U:VRTXNews ReleaseVertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX(TM), a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
2025-09-18 08:30U:VRTXNews ReleaseVertex Announces CASGEVY(TM) Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
2025-09-11 09:05U:VRTXNews ReleaseVertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
2025-08-20 16:00U:VRTXNews ReleaseVertex to Participate in Upcoming September Investor Conferences
2025-08-04 16:01U:VRTXNews ReleaseVertex Reports Second Quarter 2025 Financial Results
2025-08-04 16:01U:VRTXNews ReleaseVertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain